This site is intended only for Australian Healthcare Professionals




Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub



AboutIntroducing ENBRELAbout ENBRELTherapeutic indicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondylarthritisPlaque psoriasis & paediatric plaque psoriasisMechanism of actionMechanism of actionHalf-lifeDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPlaque psoriasisPaediatric plaque psoriasisAdministration & storageAdministrationAuto-InjectorPre-filled SyringeVialStorageEnbrel eXtendEfficacy & SafetyEfficacySustained effectivenessSafetyTolerability across indicationsImmunogenicityImmunogenicity & clinical response Immunogenicity & ENBREL®Support & ResourcesInstructions for Use Instructions for UsePatient supportResources & materialsExplore contentEventsMaterialsVideos
Therapeutic Indications

ENBREL® is registered for use across 7 indications, including paediatric indications.1

ENBREL is indicated for the treatment of:

Rheumatoid arthritis
  • Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ENBREL can be used in combination with methotrexate.1
  • Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.1

An RA patient with an increased risk of serious infections

Meet Barbara

An elderly-onset RA patient

Meet David

A young RA patient worried about treatments that lose effectiveness over time

Meet Thomas
Explore More Product Information

Before prescribing, please review full Product Information (PI).

View PI here

ENBREL is listed on the Pharmaceutical Benefits Scheme (PBS).

View PBS here

Download a copy of the ENBREL Consumer Medicine Information (CMI) for your patient.

View CMI here
CMI: Consumer Medicine Information; DMARD: disease-modifying antirheumatic drugs; PBS: Pharmaceutical Benefits Scheme; PI: Product Information; RA: Rheumatoid arthritis.
Therapeutic indications
Reference:ENBREL Product Information.

Before prescribing, please review Product Information available here​

PBS Information: Authority required for the treatment of adults with severe active rheumatoid arthritis, active ankylosing spondylitis, severe active psoriatic arthritis and severe chronic plaque psoriasis. Authority required for the treatment of patients under 18 years with severe chronic plaque psoriasis. Private and public hospital authority required for the treatment of severe active juvenile idiopathic arthritis. This product is not listed on the PBS for the treatment of non-radiographic axial spondyloarthritis. Refer to PBS Schedule for full information.​ ​

Enbrel is a ®Registered Trademark.​

PP-ENB-AUS-1044 06/23.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.


©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.


PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
PP-UNP-AUS-0551 12/23.